BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Cystic fibrosis clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for cystic fibrosis: 39 (27 sponsors; 9 newly posted in the last 180 days, 3 stopped in the last 180 days; 3 new-entrant sponsors). Momentum score 16.7, rank 38 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 11, Phase 2 15, Phase 3 7, Phase 4 0, N/A 6.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VERX | 8 | P1 3, P3 5 | 1 | 1 |
| Haisco Pharmaceutical Group Co., Ltd. | 5 | P3 2, P1 3 | 4 | 2 |
| Reistone Biopharma Company Limited new entrant | 2 | P1 2 | 2 | 1 |
| 4D Molecular Therapeutics FDMT | 1 | P2 1 | 0 | 0 |
| Aimmune Nestlé Health Science US R&D, LLC | 1 | P2 1 | 0 | 0 |
| Anagram Therapeutics, Inc. | 1 | P2 1 | 0 | 0 |
| Arcturus Therapeutics, Inc. ARCT | 1 | P2 1 | 0 | 0 |
| AstraZeneca AZN | 1 | NA 1 | 0 | 0 |
| BiomX Ltd | 1 | P2 1 | 0 | 0 |
| Boehringer Ingelheim | 1 | P2 1 | 0 | 0 |
| ChromX Health | 1 | NA 1 | 0 | 1 |
| Cognita Labs LLC | 1 | NA 1 | 0 | 0 |
| CSL Behring | 1 | P2 1 | 0 | 0 |
| Cystetic Medicines, Inc. | 1 | P1 1 | 0 | 0 |
| iSono Health, Inc. | 1 | NA 1 | 0 | 0 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 | P2 1 | 0 | 0 |
| Krystal Biotech, Inc. KRYS | 1 | P1 1 | 0 | 1 |
| Paragonix Technologies | 1 | NA 1 | 0 | 0 |
| Physio-Assist | 1 | NA 1 | 0 | 0 |
| ReCode Therapeutics | 1 | P2 1 | 0 | 0 |
| Revagenix, Inc. new entrant | 1 | P1 1 | 1 | 0 |
| Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 1 | P2 1 | 0 | 1 |
| Spirovant Sciences, Inc. | 1 | P2 1 | 0 | 1 |
| SpliSense Ltd. | 1 | P2 1 | 0 | 0 |
| Thirty Respiratory Limited | 1 | P2 1 | 0 | 0 |
New-entrant sponsors: Reistone Biopharma Company Limited, Revagenix, Inc..
Recently stopped trials
- NCT06603246 Genentech, Inc. - terminated: Sponsor's Decision A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
- NCT03460704 Zambon SpA - terminated: The study was brought to an early close in March 2022 due to major ongoing recruitment issues primarily related to the COVID-19 pandemic and Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.
- NCT07547436 Sanofi - suspended: The pause is for strategic business reasons to facilitate internal portfolio review. The pause is not due to any concerns with patient safe A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age Wi
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-28 est. | P3 | Haisco Pharmaceutical Group Co., Ltd. | NCT06660992 A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis | Non-cystic Fibrosis Bronchiectasis | recruiting | 669 |
| 2026-12-31 est. | P1/P2 | Spirovant Sciences, Inc. | NCT06526923 A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF) | Cystic Fibrosis | recruiting | 15 |
| 2027-01-08 est. | P2 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | NCT06981091 A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Pati | Non-Cystic Fibrosis Bronchiectasis | active not recruiting | 234 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | ReCode Therapeutics | NCT06237335 A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | Cystic Fibrosis | active not recruiting | 128 |
| 2026-10-30 est. | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT05444257 A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | Cystic Fibrosis | active not recruiting | 822 |
| 2026-06-25 | P2 | Sionna Therapeutics Inc. SION | NCT07108153 Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta | Cystic Fibrosis (CF) | completed | 15 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "cystic fibrosis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.